Rituximab (Rituxan) and Rituximab Biosimilars for the Treatment of Non-Oncologic Indications
Customize your policy alerts
Sign up for Blue Cross Blue Shield - North Carolina POLICY EFFECTIVE JULY 1, 2026 alerts
Get alerted when POLICY EFFECTIVE JULY 1, 2026 changes without checking for updates manually.
Monitor payer policy activity
Notification policy describing medical necessity criteria and product preferences for intravenous rituximab (Rituxan) and specified biosimilars for a range of non-oncologic autoimmune, hematologic, renal, neurologic, and pediatric indications for Blue Cross NC members.
Added multiple non-oncologic indications with associated criteria and required trial and failure of preferred rituximab biosimilar products including GPA, MPA, PV, AIHA (including cold agglutinin disease), ITP (Evans), iTTP, MS (relapsing forms), NMOSD, IgG4-RD, gMG (refractory), SLE, LN, idiopathic membranous nephropathy, pediatric idiopathic nephrotic syndrome, Wiskott-Aldrich syndrome, and antisynthetase syndrome-related ILD.
Changed requirement for trial and failure of preferred rituximab biosimilars to include Riabni in addition to Ruxience and Truxima and adjusted the designation of non-preferred product (Rituxan).
Added dosing references and maximum units for multiple indications and included HCPCS codes for biosimilars (e.g., J9312, Q5123, Q5119, Q5115).
Coverage Criteria by Indication
Non-preferred product approval conditions
Covered when ALL of the following are met for requests of rituximab (Rituxan) or a non-preferred biosimilar:
medical record documentation required
Rheumatoid arthritis (RA)
Covered when ALL of the following are met for RA:
medical record documentation required
GPA / MPA
Covered when ALL of the following are met for GPA or MPA:
medical record documentation required
Pemphigus vulgaris (PV)
Covered when ALL of the following are met for PV:
medical record documentation required
Autoimmune hemolytic anemia (AIHA)
Covered when ALL of the following are met for AIHA:
medical record documentation required
Chronic immune thrombocytopenia (ITP)
Covered when ALL of the following are met for ITP:
medical record documentation required
Immune-mediated/Acquired TTP (iTTP)
Covered when ALL of the following are met for iTTP:
medical record documentation required
Relapsing multiple sclerosis
Covered when ALL of the following are met for relapsing MS:
medical record documentation required
NMOSD
Covered when ALL of the following are met for NMOSD:
medical record documentation required
IgG4-related disease
Covered when ALL of the following are met for IgG4-RD:
medical record documentation required
Refractory generalized myasthenia gravis (MuSK+)
Covered when ALL of the following are met for refractory generalized MG (MuSK+):
medical record documentation required
Systemic lupus erythematosus (non-renal)
Covered when ALL of the following are met for SLE (non-LN):
medical record documentation required
Lupus nephritis (LN)
Covered when ALL of the following are met for biopsy-proven active LN Class III or IV (± V):
medical record documentation required
Idiopathic (primary) membranous nephropathy
Covered when ALL of the following are met for idiopathic membranous nephropathy:
medical record documentation required
Pediatric idiopathic nephrotic syndrome
Covered when ALL of the following are met for pediatric idiopathic nephrotic syndrome:
medical record documentation required
Wiskott-Aldrich syndrome (WAS) pre-gene therapy
Covered when ALL of the following are met for WAS:
medical record documentation required
Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD)
Covered when ALL of the following are met for ASyS-ILD:
medical record documentation required
Pediatric idiopathic nephrotic syndrome — Initial therapy
Covered when ALL of the following are met: (Initial therapy for pediatric idiopathic nephrotic syndrome)
medical record documentation required
medical record documentation required
medical record documentation required
Antisynthetase syndrome-related interstitial lung disease — Initial therapy
Covered when ALL of the following are met: (Initial therapy for ASyS-ILD)
medical record documentation required
General policy-wide coverage prerequisites
Covered when ALL of the following overarching requirements are met (applies to multiple listed diagnoses):
Use of rituximab in combination with certain other agents is explicitly excluded or contraindicated for specific indications. Examples in the policy include: rituximab will NOT be used in combination with inebilizumab for IgG4-related disease, rituximab will NOT be used in combination with voclosporin (Lupkynis) for lupus nephritis, and rituximab will NOT be used in combination with other specified biologic immunomodulators or disease-modifying agents for conditions such as NMOSD, MS, and generalized myasthenia gravis as noted in the indication-specific criteria.
The policy does not allow the requested rituximab agent to be used in combination with another biologic immunomodulator for treatment of the same indication. Prior authorization and documentation must show the patient will not be receiving concurrent biologic immunomodulator therapy for the requested diagnosis.
Requests for a non-preferred rituximab product (for example, Rituxan designated non-preferred) may be denied if the medical record does not document a trial and inadequate response to all preferred rituximab biosimilars (Riabni, Ruxience, Truxima) or does not document an intolerance, FDA-labeled contraindication, or serious adverse event to those preferred biosimilars.
Requests may be denied when the patient has any FDA-labeled contraindication to rituximab, when the required specialist consultation is not documented, or when hepatitis B screening (HBsAg and anti-HBc) and appropriate management if positive are not documented. The policy requires prescriber specialty or documented consultation and completion of hepatitis B screening prior to approval.
Codes and Clinical Thresholds
| rituximab (Rituxan) | intravenous infusion for administration by a healthcare professional |
| rituximab-arrx (Riabni) | intravenous infusion for administration by a healthcare professional |
| rituximab-pvvr (Ruxience) | intravenous infusion for administration by a healthcare professional |
| rituximab-abbs (Truxima) | intravenous infusion for administration by a healthcare professional |
| Any other approved rituximab biosimilars |
| D59.10 | Autoimmune hemolytic anemia unspecified |
| D69.3 | Immune thrombocytopenic purpura |
| G70.00 | Myasthenia gravis without (acute) exacerbation |
| G35.A | Multiple sclerosis, relapsing (example code listed) |
| J84.170 | Interstitial pulmonary disease with acute exacerbation (example listed) |
| L10.0 | Pemphigus vulgaris |
| M05.A | Rheumatoid arthritis with Rheumatoid factor (group noted; effective 10/1/2025) |
| N04.21 | Nephrotic syndrome with diffuse membranous glomerulonephritis |
Prior Authorization, Documentation, and Approvals
Prior authorization required for Rituxan and non-preferred biosimilars
Prior authorization is required for requests for rituximab (Rituxan) or a non-preferred rituximab biosimilar; approval is contingent on meeting the policy criteria including either documented trials and inadequate response to all preferred biosimilars or documented intolerance/contraindication/serious adverse event. Medical record documentation is required to support the applicable condition selected.
- Requests for rituximab (Rituxan) or non-preferred biosimilars must meet ONE of the policy-specified conditions: trial and inadequate response to all preferred biosimilars (Riabni, Ruxience, Truxima); OR intolerance/FDA-labeled contraindication/hypersensitivity to all preferred biosimilars; OR documented serious adverse event to all preferred biosimilars with submission of an FDA MedWatch form.
Time-limited prior authorization and dosing/quantity limits
Prior authorization is required for these products; approvals are time-limited and subject to the maximum units/dosing limits in the dosing reference table. Duration of approval is 180 days (one-time, single-dose lifetime) for Wiskott-Aldrich syndrome and 365 days for all other diagnoses.
- Wiskott-Aldrich syndrome (WAS): 180 days (one-time, single-dose per lifetime).
- All other diagnoses: 365 days (1 year).
- Requested quantity must not exceed maximum units allowed for the duration of approval as listed in the dosing reference table (product-specific maximums are provided per HCPCS/product).
Required trial of all preferred rituximab biosimilars before non-preferred product
Step therapy requires that the patient has tried and had an inadequate response to all preferred rituximab biosimilars (Riabni [rituximab-arrx], Ruxience [rituximab-pvvr], and Truxima [rituximab-abbs]) before a non-preferred rituximab product will be considered, unless there is documented intolerance, FDA-labeled contraindication, hypersensitivity, or a serious adverse event to the preferred agents.
- Preferred biosimilars named: rituximab-arrx (Riabni), rituximab-pvvr (Ruxience), rituximab-abbs (Truxima).
- Allowances: documented intolerance, FDA-labeled contraindication, hypersensitivity, or documented serious adverse event (with FDA MedWatch submission) to preferred agents may substitute for trial/failure.
Updated preferred biosimilar list required for step therapy
The policy explicitly lists the preferred rituximab biosimilars required for step therapy as Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs); trial and failure of these agents (or documented intolerance/contraindication/serious adverse event) is required prior to approval of a non-preferred rituximab product.
- January 2026 update added Riabni to the preferred agent list in addition to Ruxience and Truxima.
- Policy change effective July 2026 reiterates required trial/failure of the preferred biosimilars for multiple added non-oncologic indications.
Medical record evidence required for prior trials, adverse events, and diagnosis-specific tests
Medical record documentation must demonstrate prior trials and inadequate responses, intolerances, FDA-labeled contraindications, hypersensitivity, or serious adverse events to preferred biosimilars and must support diagnosis-specific requirements such as biopsy results, antibody or ADAMTS13 testing, and other objective measures.
- Documentation of prior trials and inadequate responses or intolerances to the preferred rituximab biosimilars is required when relying on step-therapy exceptions.
- If denying step therapy due to serious adverse events, prescriber must submit an FDA MedWatch Adverse Event Reporting Form (documentation required).
- Diagnosis-specific supporting records (e.g., biopsy for lupus nephritis, antibody tests for NMOSD, ADAMTS13 activity for iTTP) must be included in the medical record.
Documentation of diagnosis confirmation, prior therapy trials, and baseline severity (including hepatitis B screening)
Submit documentation confirming diagnosis, prior trials and inadequate response or intolerance to specified agents, and baseline objective severity measures (e.g., PFTs, HRCT, glucocorticoid use); hepatitis B screening (HBsAg and anti-HBc) must be completed and, if positive, treated prior to or at therapy initiation.
- Diagnosis confirmation and required baseline objective measures (e.g., proteinuria, PFTs, HRCT) per indication must be in the medical record.
- Document prior trials of steroid-sparing agents, immunosuppressants, or biologics and inadequate response or intolerance where required.
- Hepatitis B screening (HBsAg and anti-HBc) required; if positive, documentation that therapy for hepatitis B has begun is required.
Coverage conditions for non-preferred rituximab products
Requests for non-preferred rituximab products will be considered only if the patient has trialed and had an inadequate response to ALL preferred biosimilars (Riabni, Ruxience, Truxima) or there is medical record documentation of intolerance, FDA-labeled contraindication, hypersensitivity, or a documented serious adverse event to all preferred biosimilars.
- If claiming intolerance/contraindication or hypersensitivity to preferred agents, documentation must indicate the reaction is NOT expected to occur with the requested non-preferred product.
- For documented serious adverse events to preferred agents, prescriber must submit a completed FDA MedWatch form.
Denial risk: specialist prescriber, consultations, hepatitis B screening, and combination biologics
Approval risk increases if the prescriber is not a specialist for the patient’s diagnosis, if required specialist consultation is not documented, or if hepatitis B screening and treatment (when positive) are not documented; use of the requested agent in combination with another biologic immunomodulator for the same indication is not allowed and is a denial risk.
- Prescriber must be a relevant specialist or have consulted a specialist for the diagnosis (examples listed by diagnosis in policy).
- Patient must not be using the requested agent in combination with another biologic immunomodulator for the requested indication.
- Documented hepatitis B screening (HBsAg and anti-HBc) and initiation of hepatitis B therapy if positive are required to avoid denial.
Background
Rituximab and its biosimilars are intravenous anti-CD20 monoclonal antibodies that target CD20-positive B cells and are used across multiple autoimmune, hematologic, renal, neurologic, and pediatric indications. The policy aligns FDA-approved and commonly used non-oncologic indications with prior authorization, step therapy, and documentation expectations to manage product selection and safety monitoring.
Definitions and Clinical Thresholds
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.